




ELSEVIER

Archivos
de Cardiología
de México

www.elsevier.com.mx



BASIC RESEARCH

Comparison of homocystinemia and MTHFR 677CT polymorphism with Framingham Coronary Heart Risk Score

Luis Gariglio^a, Stephanie Riviere^b, Analía Morales^b, Rafael Porcile^a,
Miguel Potenzoni^a, Osvaldo Fridman^{b,c,*}

^a Hospital Universitario, Universidad Abierta Interamericana, Buenos Aires, Argentina

^b Centro de Altos Estudios en Ciencias Humanas y de la Salud, Universidad Abierta Interamericana, Buenos Aires, Argentina

^c Consejo Nacional de Investigaciones Científicas y Técnicas, Argentina

Received 30 July 2013; accepted 16 December 2013

KEYWORDS

Framingham Coronary Heart Disease Risk Score;
Homocysteine;
Methylenetetrahydrofolate reductase;
C677T polymorphism;
Argentina

Abstract

Objective: The Framingham Coronary Heart Disease Risk Score is an important clinical tool. The aim of this cross-sectional study was to compare plasma homocysteine levels and polymorphism 677CT MTHFR with this score to determine the utility of these new biomarkers in clinical practice.

Methods: Plasma homocysteine levels determined by chemiluminescence and polymorphism 677CT MTHFR, detected by PCR-RFLP, were compared with Framingham coronary risk score in a cross-sectional survey on 68 men and 165 women.

Results: Coronary heart disease risk augmented with an increase in the quartile of plasma homocysteine. In the 2nd, 3rd and 4th quartile of plasma homocysteine, men showed significantly ($P < 0.001$) higher risk than women. For the highest quartile of plasma homocysteine, OR of high-risk (10-year risk $\geq 20\%$) compared with the lowest quartile was 17.45 (95% CI: 5.79–52.01). Frequencies of CT and TT genotype and T allele were not over-represented in the individuals with score $\geq 10\%$. The higher plasma homocysteine concentrations in individuals with score $\geq 10\%$ with respect to those with low risk ($P < 0.005$ and $P < 0.001$) were not due to the presence of T allele. The T allele (CT + TT genotypes) of the MTHFR C677T polymorphism was not significantly associated with an increased risk of coronary disease (OR = 1.09, 95% CI = 0.50–2.39, $P = 0.844$).

Conclusions: The present study demonstrated an association between plasma homocysteine levels and the severity of coronary heart disease estimated with the Framingham coronary risk score, and this association appeared to be independent on the genotype of MTHFR. We postulate that plasma homocysteine is effective enough, considered even in isolation.

© 2013 Instituto Nacional de Cardiología Ignacio Chávez. Published by Masson Doyma México S.A. All rights reserved.

* Corresponding author at: Av. Montes de Oca 745 (C1270AAH), Buenos Aires, Argentina.

E-mail address: osvaldo.fridman@gmail.com (O. Fridman).

PALABRAS CLAVE

Puntuación del riesgo coronario de Framingham; Homocisteína; Metilentetrahidrofolato reductasa; Polimorfismo C677T; Argentina

Comparación de homocisteinemia y polimorfismo 677CT MTHFR con el Escore Framingham de Riesgo Coronario**Resumen**

Objetivo: La puntuación del riesgo coronario de Framingham es una importante herramienta clínica. El objetivo del presente estudio transversal fue comparar los niveles plasmáticos de homocisteína plasmática y el polimorfismo 677CT de la MTHFR con esta herramienta para determinar la utilidad de estos nuevos biomarcadores en la práctica clínica.

Métodos: Los niveles de homocisteína plasmática determinados por quimioluminiscencia y el polimorfismo 677CT MTHFR por PCR-RFLP fueron comparados con la puntuación del riesgo coronario de Framingham en un estudio transversal sobre 68 hombres y 165 mujeres.

Resultados: El riesgo de enfermedad coronaria aumentó con el incremento en los cuartiles de homocisteína plasmática. En el segundo, tercero y cuarto cuartil de homocisteína plasmática los hombres mostraron significativamente ($p < 0.001$) mayor riesgo que las mujeres. Para el cuartil más alto de homocisteína plasmática, la OR de riesgo alto (riesgo a 10 años $\geq 20\%$) comparado con el cuartil más bajo fue 17,45 (IC 95%: 5,79-52,01; $p < 0.001$). Las frecuencias de los genotipos CT y TT y del alelo T no estuvieron aumentados en los individuos con una puntuación $\geq 10\%$. Las mayores concentraciones de homocisteína plasmática en los individuos con una puntuación $\geq 10\%$ respecto a los de bajo riesgo ($p < 0.005$ y $p < 0.001$) no se debieron a la presencia del alelo T. El alelo T (genotipos CT + TT) del polimorfismo MTHFR C677T no estuvo significativamente asociado con mayor riesgo de enfermedad coronaria (OR = 1.09, IC 95% = 0.50-2.39, $p = 0.844$).

Conclusiones: El presente estudio mostró una asociación entre los niveles de homocisteína plasmática y la severidad de la enfermedad coronaria estimada con el algoritmo de puntuación de riesgo coronario de Framingham y esta asociación resultó ser independiente del genotipo de MTHFR. Postulamos que la homocisteína plasmática es lo suficientemente eficaz, estudiada incluso aisladamente.

© 2013 Instituto Nacional de Cardiología Ignacio Chávez. Publicado por Masson Doyma México S.A. Todos los derechos reservados.

Introduction

Cardiovascular diseases (CVD) are some of the leading causes of death. The Framingham Coronary Heart Disease Risk Score (FCRS), modified by the National Cholesterol Education Program-Adult Treatment Panel III (NCEP ATP III) guideline, based on the predictive capacities of the cardiovascular risk factors including sex, age, high blood pressure, total cholesterol (TC) level, high density lipoprotein cholesterol (HDL-C) level, diabetes mellitus, and cigarette smoking, has been adopted as a standard approach to the prediction of risk of coronary heart disease (CHD).^{1,2} This score is an important clinical tool although not all persons at high CHD risk are identified by the FCRS. In order to improve CHD risk prediction, other cardiovascular risk markers have been evaluated. Among those, plasma homocysteine (tHcy) is recognized as a risk factor³ independent of conventional risk factors such as diabetes mellitus, smoking and hyperlipidemia.⁴ However, few data are available comparing tHcy levels with calculated FCRS.^{5,6} Homocysteine is re-methylated to methionine by the enzyme methionine synthase that requires 5-methyltetrahydrofolate (5-MTHF) as methyl donor and vitamin B12 as cofactor. This donor is synthesized by the enzyme methylenetetrahydrofolate reductase (MTHFR) from 5,10-methylene-tetrahydrofolate.⁷ Reduction in its activity can be caused as a result of genetic and non-genetic factors.⁸ There are 24 genetic polymorphisms associated with this gene and four (203G > A,

677C > T, 1298A > C and 1793G > A) have been studied in relation to different pathologies.⁹ Within these SNPs, 677C > T, resulting in the replacement of alanine for valine, produces a thermolabile enzyme with decreased MTHFR specific activity. As a result, homozygous 677TT has 30% of residual activity and heterozygous 677CT has 70% when compared to 677CC variant,^{10,11} resulting in an enhanced plasma level of tHcy and low of folate.¹¹ Several studies suggest that this SNP is a genetic risk factor for vascular disease;^{8,12} however others could not confirm this association.^{13,14} Various meta-analysis studies arrived at different conclusions about the association of an increase in tHcy levels with risks of vascular diseases in patients with MTHFR mutation.^{15,16} To determine whether these new biomarkers are useful in clinical practice, in this study we examined the association between tHcy levels and polymorphism 677CT MTHFR with the FCRS at population level.

Methods

We carried out a cross-sectional study comprising 68 men and 165 women aged 18-87 years, randomly selected in three health centers from Buenos Aires City, belonging to the University Hospital of Universidad Abierta Interamericana. They were all physically active. The exclusion criteria were pregnancy, use of any type of (multi-)vitamin tablet in the preceding year and younger than 18 years. Written informed

consent was obtained from all participants before the study began. The hospital local ethics committee approved the study protocol in accordance with the Declaration of Helsinki as revised in 1983. A questionnaire with clinical data was completed by all subjects on the day of enrollment. Participants were classified as hypertensive if they were taking antihypertensive medication. The risk factors of vascular disease recorded in this study were hypertension ($\geq 140/90$ mmHg), diabetes (glycemia ≥ 6.96 mmol/L), hyperlipidemia (HDL-C < 1.04 mmol/L for men and < 1.30 for women, and TC > 5.20 mmol/L).¹⁷ A self-reported questionnaire was used to collect the subjects' data including their past medical history, smoking status, and the prescribed drugs.

Blood collection

All blood samples were collected after an overnight fast (>10 h) by venipuncture into an EDTA containing tube. A separated aliquot was kept for DNA extraction. Plasma samples were obtained by double centrifugation at room temperature for 15 min at $2000 \times g$. The plasma aliquots were immediately frozen at -80°C until use.

Laboratory measurements

Biochemical measurements, including glycemia, TC, and HDL-C, were carried out using the Metrolab 2300 auto-analyzer. Plasma tHcy was determined by chemiluminescence in a Bayer Corp. ADVIA Centaur apparatus (Leverkusen, Germany).

MTHFR mutation analysis. DNA extraction

Genomic DNA was isolated from nucleated blood cells using the FlexiGene DNA Kit QIAGEN® GmbH, (Hilden, Germany) following the manual's instructions. DNA samples were kept at -80°C until analyzed.

PCR-RFLP analysis

The 677C>T MTHFR gene mutation was detected by the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method according to Frosst et al.¹¹ Briefly, about 50–80 ng DNA samples were amplified in a final volume of $25 \mu\text{L}$ containing $1 \times$ PCR buffer with $2.0 \text{ mmol/L MgCl}_2$, 0.75 unit GoTaq DNA Polymerase (Promega) $200 \mu\text{mol/L dNTP}$, and $0.5 \mu\text{mol/L}$ of each primer (5'-TGAAGGAGGTGCTGGGA-3' and 5'-AGGACGGTGCGGTGAGAGTG-3'). PCR was performed in an Eppendorf Mastercycler Personal thermocycler (Germany), and the profile consisted of an initial melting step of 5 min at 94°C ; followed by 45 cycles of 40 s at 94°C , 50 s at 62°C , and 40 s at 72°C ; and a final elongation step of 7 min at 72°C . The restriction enzyme *Hinf* I (Promega, UK) was used to distinguish the 677 C>T polymorphism, since the polymorphic allele presents a *Hinf* I restriction site.

The 677CC variant had a single band representing the entire 198-bp fragment, and the heterozygous genotype 677CT resulted in three fragments of 198, 175 and 23 bp,

while the homozygous 677TT for the MTHFR mutation results in 2 fragments of 175 and 23 bp. Finally the products of the *Hinf* I digestion were electrophoresed on a 3% agarose gel. To ensure quality control, genotyping was performed blindly, and random samples were tested twice by different persons. The participants were categorized as homozygous (CC), heterozygous (CT), or homozygous (TT) for the thermolabile variant.

Calculation of 10-year CHD risk

A 10-year CHD risk was calculated using FCRS modified by the NCEP ATP III guideline that uses major independent risk factors including cigarette smoking, blood pressure, TC, HDL-C, age and type-2 diabetes.^{1,2} Individual risk factor scores were assigned on the basis of age, TC, systolic blood pressure, HDL-C, and smoking status, and were summed to determine the 10-year absolute risk. The absolute risk percentage in 10 years was calculated, which can be classified as low risk (<10%), intermediate risk (10–20%) and high risk > 20%).

Statistical analysis

For continuous variables, values were presented as mean \pm standard error (SE) or median (inter-quartile range), as appropriate. Differences between the examined quantitative parameters were compared by the Mann–Whitney *U*-test. Categorical data were expressed as the number of subjects (percentage). The study subjects were grouped into quartiles according to the circulating levels of tHcy. Kruskal–Wallis test was used to test the difference in the 10-year CHD risk among quartiles of biomarkers, followed by the post hoc Bonferroni test for multiple comparisons. Multiple logistic regression analysis was performed to determine the odds ratio (OR) of high-risk for CAD (10-year risk $\geq 10\%$) in each quartile of biomarkers. Deviation of the genotype distribution from the Hardy–Weinberg equilibrium was determined by χ^2 test/Fisher's exact test. All tests were 2-tailed. Statistical analyses were performed using the SPSS software version 16.0 (SPSS Inc., Chicago, IL, USA). A *P* value of <0.05 was considered statistically significant.

Results

The population sample was composed of 65 men and 168 women aged between 18 and 87 years. Hypertension was present in 71 (30.5%) subjects, cigarette smokers 82 (35.2%) and diabetics 16 (6.7%) (Table 1). The prevalence of genotypes determined in the overall sample population of this study were: CC 43.4%, CT 47.2% and TT 9.4%. The frequencies of C and T allele were 0.67 and 0.33, respectively, and this polymorphism was in Hardy–Weinberg equilibrium ($\chi^2 = 1.041$, df = 1, *P* = 0.308). These frequencies are consistent with other studies of this variant.^{15,18} Table 1 shows the distribution of the variables' average values according to the seriousness of CHD risk score. Individuals with the lowest CHD risk score had the youngest age, the lowest concentrations of TC, highest concentrations of HDL-C, and lowest percentage of hypertensive, cigarettes smokers, and diabetics. The 10-year CHD risk augmented with an increase in the quartile of tHcy (*P* < 0.001) (Fig. 1). The 10-year CHD risk in

Table 1 10-year CHD risk characteristics of subjects in the overall sample and stratified by risk levels.

	Overall sample	10-year CHD risk		
		Low	Intermediate	High
N	233	176	40	17
Age (years)	45.9 ± 16.4	40.8 ± 14.6 ^a	62.3 ± 11.9 ^b	58.9 ± 9.3 ^b
Total cholesterol (mmol/L)	5.39 ± 1.27	5.17 ± 1.12 ^a	5.92 ± 1.32 ^b	6.65 ± 1.50 ^b
HDL-C (mmol/L)	1.41 ± 0.37	1.46 ± 0.37 ^a	1.36 ± 0.33 ^a	1.04 ± 0.19 ^b
Hypertension, n (%)	71 (30.5)	34 (19.3) ^a	25 (62.5) ^b	12 (70.6) ^b
Current smoker, n (%)	82 (35.2)	57 (32.4) ^a	12 (30.0) ^a	13 (76.5) ^b
Diabetes, n (%)	16 (6.9)	6 (3.4) ^a	2 (5.0) ^a	8 (47.1) ^b

Age, total cholesterol and HDL-C expressed as mean ± SD.

Different letters indicate significant differences ($p < 0.05$).




Figure 1 The 10-year CHD risk by quartiles of homocysteine. The 10-year CAD risks are different among quartiles of homocysteine. Q1: 1st quartile ($\leq 6.39 \mu\text{mol/L}$). Q2: 2nd quartile ($6.40\text{--}7.29 \mu\text{mol/L}$). Q3: 3rd quartile ($7.30\text{--}8.90 \mu\text{mol/L}$). Q4: 4th quartile ($\geq 8.91 \mu\text{mol/L}$).

the 4th quartile of tHcy was significantly higher than those in the other three quartiles ($P < 0.001$). Gender differences were also found in the 10-year CHD risk for levels of tHcy. Fig. 2 shows that in 2nd, 3rd and 4th quartiles of tHcy, men exhibited significantly ($P < 0.001$) more risk than women.

The OR for 10-year CHD risk $\geq 10\%$ in 2nd ($6.40\text{--}7.29 \mu\text{mol/L}$), 3rd ($7.30\text{--}8.90 \mu\text{mol/L}$) and 4th




Figure 2 The 10-year CHD risk by quartiles of homocysteine in male and female. The 10-year CAD risks. Gender differences in quartiles of homocysteine. Q1: 1st quartile ($\leq 6.39 \mu\text{mol/L}$). Q2: 2nd quartile ($6.40\text{--}7.29 \mu\text{mol/L}$). Q3: 3rd quartile ($7.30\text{--}8.90 \mu\text{mol/L}$). Q4: 4th quartile ($\geq 8.91 \mu\text{mol/L}$).

($>8.91 \mu\text{mol/L}$) quartiles of tHcy compared to 1st quartile ($<6.39 \mu\text{mol/L}$) were 2.81 (95% CI: 0.87–8.99; NS), 3.51 (95% CI: 1.11–11.01; NS) and 17.45 (95% CI: 5.79–52.01; $P < 0.001$), respectively (Fig. 3). The tHcy, dichotomized with cut off point $11 \mu\text{mol/L}$, was also calculated. This cut off point was chosen because it was proposed in previous work^{19,20} in population samples from the same city as this work. The 10-year CHD risk $\geq 10\%$ increased more than 11-fold (OR = 11.67, $P < 0.001$) with respect to tHcy lower than or equal to $11 \mu\text{mol/L}$, when tHcy was higher than $11 \mu\text{mol/L}$ (data not shown). Comparison of the intermediate and high risk groups against the low risk group showed that the frequency of CT and TT genotype and T allele were not over-represented in the individuals with FRS $\geq 10\%$ (Table 2), even if the risk of CHD was compared within the subjects with the CC genotype and the combined number of subjects with T allele (CT heterozygotes and TT homozygotes).

Table 3 shows plasma concentrations of tHcy analyzed by genotypes in the low, intermediate and high risk of CHD. The higher tHcy concentrations observed in the individuals with FRS $\geq 10\%$ (intermediate, high and intermediate plus high) with respect to those with low risk ($P < 0.005$ and $P < 0.001$) were not due to the presence of the T allele.

The present study also showed that in subjects in the 4th quartile of tHcy, the presence of the T allele (CT + TT genotypes) of the MTHFR C677T polymorphism was not significantly associated with an increased risk of CHD (FRS $> 10\%$) (OR = 1.09, 95% CI = 0.50–2.39, $P = 0.844$) (data not shown).

Discussion

Several risk calculators are available to adopt preventive interventions of CVD, including the ATP III and traditional FCRS.¹ This simplified tool categorizes adults into 3 risk categories, low (<10% over 10 years), intermediate (10–20%), and high (>20% risk), on the basis of age, sex, systolic blood pressure, serum TC level, HDL-C level, cigarette smoking and diabetes history.¹

Homocysteine is of epidemiologic interest as a potential risk factor. The strong association between raised concentrations of tHcy and CHD has been recognized since




Figure 3 OR of high risk for CHD (10-year risk > 10%) by homocysteine levels. Q1: 1st quartile. Q2: 2nd quartile. Q3: 3rd quartile. Q4: 4th quartile.

Table 2 Distribution of genotypes and allele frequencies of the MTHFR 677CT polymorphism in low, intermediate and high risk groups.

	CC n	CT n	TT n	CT + TT n	N	C Allele	T Allele
10-year CHD risk							
<i>Low</i>	76	83	17	100	176	235	117
<i>Intermediate</i>	16	21	3	24	40	53	27
Odds ratios	1	1.202	8.838	1.140		1	1.023
IC (95%)		0.589–2.450	0.237–3.023	0.571–2.275			0.614–1.705
p value		0.715	1.000	0.860			1.000
<i>High</i>	9	6	2	8	17	24	10
Odds ratios	1	0.610	0.993	0.676		1	0.837
IC (95%)		0.216–1.731	0.224–4.530	0.257–1.779			0.393–1.783
P value		0.425	1.000	0.455			0.707
<i>Intermediate + high</i>	25	27	5	32	57	77	37
Odds ratios	1	0.989	0.894	0.973		1	0.965
IC (95%)		0.531–1.842	0.311–2.593	0.535–1.769			0.616–1.512
p value		1.000	1.000	1.000			0.909

1969.²¹ This relationship between tHcy level and risk for cardiovascular events was supported in a large number of cohort studies²² and has been repeatedly described by various populations.³ Ganji and Kafai²³ in a meta-analysis of a

subset of studies reported that each 5- $\mu\text{mol/L}$ increase in tHcy level confers an approximately 9% increase in the risk for CHD events and is independent from traditional CHD risk factors.

Table 3 Homocysteinemia in risk groups classified by genotypes of polymorphism 677CT MTHFR.

10-year CHD risk	Genotype (677CT MTHFR)			
	CC	CT	TT	CT + TT
Low	7.53 ± 0.27 (76)	7.13 ± 0.21 (83)	7.27 ± 0.31 (17)	7.16 ± 0.18 (100)
Intermediate	10.38 ± 1.44 (16)*	10.52 ± 0.15 (21)**	13.08 ± 0.79 (3)**	10.35 ± 0.59 (24)**
High	8.73 ± 0.80 (9)	9.85 ± 1.90 (6)*	8.52 ± 1.02 (2)	9.52 ± 1.42 (8)*
Intermediate + High	9.79 ± 1.21 (25)*	10.38 ± 0.94 (27)**	11.26 ± 0.88 (5)**	10.51 ± 0.80 (32)**

Homocysteinemia in $\mu\text{molar} \pm \text{SE}$. Number of subjects in parenthesis.

* $P < 0.005$.

** $P < 0.001$ respect the same genotype with low risk.

In order to have an estimate of the power of hyperhomocysteinemia as a risk factor for CHD, in the present study we compared plasma tHcy levels with the universally accepted FCRS.

Our data on factors related with the FCRS (Table 1) indicated that CHD risk score increased with age and TC and decreased with HDL-C, and was related to hypertension, diabetes and smoking.

In this study, the average tHcy level was significantly higher in subjects with FCRS > 10% than in persons with lower FCRS and a highly significant correlation between the tHcy levels and the FCRS was observed (Fig. 1). When both sexes were studied separately, in the three highest quartiles of tHcy, men showed significantly more risk than women (Fig. 2), reinforcing the predictive power of the tHcy in isolation. Gender difference in tHcy can be explained considering that sex hormones have effects on methionine metabolism, the level of creatinine is higher in men, the musculoskeletal system of men is usually more developed and has a larger volume and mass compared to women, and plasma level of folic acid and vitamin B12 is different between men and women.²⁴ Besides, the highest quartile of tHcy showed a significantly higher OR of high-risk for CHD (10-year risk ≥ 10%), which was also observed when serum tHcy was dichotomized with the cut off point 11 μmol/L (data not shown).

These cross-sectional data indicating that plasma concentration of tHcy is significantly associated with calculated FCRS are in close agreement with those of recent studies, which used NECP ATP III guideline.^{25–27} For decades the FCRS has been used to predict the 10 year risk of developing coronary heart disease, the search of a more accurate measure of cardiovascular disease risk is very relevant. It is known that cardiovascular disease is not accurately predicted by classic risk factors such as those included in the FCRS, separately. By contrast, as we found in this investigation, a single measurement of tHcy accurately identifies those at high risk of cardiovascular disease. These results suggest that risk identification for primary prevention of cardiovascular disease can be based on plasma concentrations of tHcy in isolation.

Montalescot et al.²⁸ demonstrated that the presence of hypertension, one of the risk factors considered within the FCRS, and hyperhomocysteinemia were associated with more severe coronary atherosclerosis. Nevertheless, other studies found no correlation between tHcy levels and the extent and severity of CHD.^{29–31}

The development of CHD is believed to be largely under genetic control. In previous studies we demonstrated that *MTHFR* 677CT mutation may contribute to hypertension or affect the development of hypertension through hyperhomocysteinemia,²⁰ and we also found an association between this polymorphism and tHcy with hypertension, which is manifested with age in women. We concluded that the differences observed in sex and age could be the result of endocrine activity, since also the hormonal status may modify the phenotypic expression of this genetic variant.^{25,32} In this context, in the present work, we also wanted to determine whether these variables are associated with the FCRS. In our population, this polymorphism did not correlate with the risk of CHD calculated by the FCRS. We also could observe that the higher tHcy levels in persons with FCRS ≥ 10% were independent to the T allele. We concluded

that this *MTHFR* C677T polymorphism was not associated with the risk of CHD calculated with the FCRS.

Our results are in accord with many investigations that failed to detect an association of the *MTHFR* gene variation with the presence of CHD.^{13,25,33–35} Although other studies showed the relationship of the *MTHFR* gene polymorphism with the extent of CHD.^{8,36,37} These discrepancies could, at least in part, be explained by gene interactions and life-style which were also postulated to be associated with CHD^{38–41} and might interfere to a different degree with the link between the *MTHFR* 677CT gene variation and the risk of CHD. Genetic factors are not the only cause of an increase in the plasma tHcy. Many other demographic and lifestyle factors, such as age, gender, folate intake through food, smoking, coffee and alcohol consumption, use of certain medications, and several diseases can affect the tHcy concentration.²⁵

Although it has been shown that TT homozygotes have higher tHcy levels than the other *MTHFR* C677T genotypes,¹¹ Jacques et al.⁴² demonstrated that these differences disappeared when individuals had folate levels greater than 15.4 nmol/l, suggesting that *MTHFR* C677T TT homozygotes require folate supplementation to regulate plasma tHcy concentrations.

A potential weakness in our study was the lack of folate determination. This was caused by the fact that it is not currently available as a procedure in our laboratories. Therefore, we do not have direct evidence that the TT genotype was also associated with reduced plasma levels of folate.

The relationship between plasma tHcy and other mutations in the *MTHFR* gene such as the A1298C in our studied group remains to be addressed and in fact, it is in progress. Also, our results must be analyzed considering that Argentina is a country with a heterogeneous population, which results in cultural, socioeconomic and ethnic diversity, particularly in the metropolitan area. It is important to note that the frequency of the *MTHFR* 677T allele is known to vary substantially among different ethnic populations.⁴³ Finally, in our study, the following limitations must be considered. First, the sample size may limit the power of testing a significant association between *MTHFR* 677TT and FCRS. However, the associations that have reached statistical significance in this context of limited sample size may be thought as valid and reproducible in larger samples. In the future, large prospective studies are needed in order to confirm our findings and analyze the possible benefits of prevention and treatment.

Conclusions

Our findings showed an association between tHcy levels and the severity of CHD estimated with the FCRS algorithm, and this association appeared to be independent on the genotype of *MTHFR*. Since the phenotypic expression of the T allele is highly dependent on many other variables, it is reasonable that in average its presence does not correlate with FCRS. We postulate that determination of plasma homocysteine is effective enough as predictor of risk of CHD, considered even in isolation.

Funding

This work was supported by a grant from the Universidad Abierta Interamericana (UAI).

Conflict of interest

The authors declare having no conflict of interest.

References

1. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998;97:1837–47.
2. Talbert RL. New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III. *Am J Manag Care*. 2002;8 12 Suppl.:S301–7.
3. Forouhi NG, Sattar N. CVD risk factors and ethnicity – a homogeneous relationship? *Atheroscler Suppl*. 2006;7:11–9.
4. Sainani GS, Sainani R. Homocysteine and its role in the pathogenesis of atherosclerotic vascular disease. *J Assoc Physicians India*. 2002;50 Suppl.:5–8.
5. de Ruijter W, Westendorp RGJ, Assendelft WJJ, et al. Use of Framingham Risk Score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. *Br Med J*. 2009;338:a3083.
6. Ovbiagele B, Liebeskind DS, Kim D, et al. Management of asymptomatic coronary artery disease in patients with stroke and patients with transient ischemic attack. *Stroke*. 2009;40:3407–9.
7. Dudman NP, Guo XW, Gordon RB, et al. Human homocysteine catabolism: three major pathways and their relevance to development of arterial occlusive disease. *J Nutr*. 1996;126 4 Suppl, 1295S–300S.
8. Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. *Am J Hum Genet*. 1996;58:35–41.
9. Safarinejad MR, Shafiei N, Safarinejad S. Relationship between genetic polymorphisms of methylenetetrahydrofolate reductase (C677T, A1298C, and G1793A) as risk factors for idiopathic male infertility. *Reprod Sci*. 2011;18:304–15.
10. Kang SS, Zhou J, Wong PWK, et al. Intermediate homocysteinemia: a thermolabile variant of methylentetrahydrofolate reductase. *Am J Hum Genet*. 1988;43:414–21.
11. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. *Nat Genet*. 1995;10:111–3.
12. Christensen B, Frosst P, Lussier-Cacan S, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. *Arterioscler Thromb Vasc Biol*. 1997;17:569–73.
13. Brugada R, Marian AJ. A common mutation in methylene-tetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. *Atherosclerosis*. 1997;128:107–12.
14. Thogersen AM, Nilsson TK, Dahlen G, et al. Homozygosity for the C677→T mutation of 5,10-methylenetetrahydrofolate reductase and total plasma homocyst(e)ine are not associated with greater than normal risk of a first myocardial infarction in northern Sweden. *Coron Artery Dis*. 2001;12:85–90.
15. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *Br Med J*. 2002;325:1202–6.
16. Lewis SJ, Ebrahim S, Smith GD. Meta-analysis of MTHFR 677C-T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? *Br Med J*. 2005;331:1053 (only one page).
17. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *J Am Med Assoc*. 2001;285:2486–97.
18. Heux S, Morin F, Lea RA, et al. The ethylentetrahydrofolate reductase gene variant (C677T) as a risk factor for essential hypertension in Caucasians. *Hypertens Res*. 2004;27:663–7.
19. Castañón MM, Lauricella AM, Kordich L, et al. Plasma homocysteine cutoff values for venous thrombosis. *Clin Chem Lab Med*. 2007;45:232–6.
20. Fridman O, Porcile R, Vanasco V, et al. Study on homocysteine levels and methylentetrahydrofolate reductase gene variant (C677T) in a population of Buenos Aires city. *Clin Exp Hypertens*. 2008;30:574–84.
21. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. *Am J Pathol*. 1969;56:111–28.
22. Humphrey LL, Fu R, Rogers K, et al. Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis. *Mayo Clin Proc*. 2008;83:1203–12.
23. Ganji V, Kafai MR. Population reference values for plasma total homocysteine concentrations in US adults after the fortification of cereals with folic acid. *Am J Clin Nutr*. 2006;84:989–94.
24. Graham IM, Daly IE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: The European concerted Action Project. *J Am Med Assoc*. 1997;277:1775–81.
25. De Bree A, Verschuren WMM, Kromhout D, et al. Determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. *Pharmacol Rev*. 2002;54:599–618.
26. Cho DY, Kim KN, Kim KM, et al. Combination of high-sensitivity C-reactive protein and homocysteine may predict an increased risk of coronary artery disease in Korean population. *Chin Med J (Engl)*. 2012;125:569–73.
27. Park CS, Ihm SH, Yoo KD, et al. Relation between C-reactive protein, homocysteine levels, fibrinogen, and lipoprotein levels and leukocyte and platelet counts, and 10-year risk for cardiovascular disease among healthy adults in the USA. *Am J Cardiol*. 2010;105:1284–8.
28. Montalescot G, Ankri A, Chadefaux-Vkemans B, et al. Plasma homocysteine and the extent of atherosclerosis in patient with coronary artery disease. *Int J Cardiol*. 1997;60:295–300.
29. Bozkurt A, Toyaksi H, Acartürk E, et al. The Effects of hyperhomocysteinemia on the presence, extent, and severity of coronary artery disease. *Jpn Heart J*. 2003;44:357–68.
30. Bozkurt E, Keles S, Acikel M, et al. Plasma homocysteine levels and the angiographic extent of coronary artery disease. *Angiology*. 2004;55:265–70.
31. Bokhari SW, Bokhari ZW, Zell JA, et al. Plasma homocysteine levels and the left ventricular systolic function in coronary artery disease patients. *Coron Artery Dis*. 2005;16:153–61.
32. Fridman O, Porcile R, Morales AV, et al. Association of methylenetetrahydrofolate reductase gene C677T polymorphism with hypertension in older women in a population of Buenos Aires City. *Clin Exp Hypertens*. 2013;35:159–66.
33. Anderson JL, King GJ, Thomson MJ, et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. *J Am Coll Cardiol*. 1997;30:1206–11.

34. Reinhardt D, Sigusch HH, Vogt SF, et al. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease. *Eur J Clin Invest.* 1998;28:20–3.
35. Abbate R, Sardi I, Pepe G, et al. The high prevalence of thermolabile 5–10 methylenetetrahydro-folate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). *Thromb Haemost.* 1998;79:727–30.
36. Morita H, Taguchi J, Kurihara H, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. *Circulation.* 1997;95:2032–6.
37. Gardemann A, Weidemann H, Philipp M, et al. The TT genotype of the methylenetetrahydrofolate reductase C 677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease. *Eur Heart J.* 1999;20:584–92.
38. Ko YL, Ko YS, Wang SM, et al. Angiotensinogen and angiotensin I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese. *Hum Genet.* 1997;100:210–4.
39. Garin MC, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. *J Clin Invest.* 1997;99:62–6.
40. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. *Atherosclerosis.* 1995;115:243–53.
41. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidised low density lipoprotein. *J Clin Invest.* 1995;96:2882–91.
42. Jacques PF, Boston AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. *Circulation.* 1996;93:7–9.
43. Franco RF, Araújo AG, Guerreiro JF, et al. Analysis of the 677 C→T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. *Thromb Haemost.* 1998;79:119–21.